Customize At1g50980 Antibody

Description

Potential Explanations for the Absence of "At1g50980 Antibody"

Gene Identifier Misinterpretation:
- "At1g50980" may refer to a gene identifier in non-human organisms (e.g., Arabidopsis thaliana, where "At" denotes the species). Antibodies targeting plant-specific proteins are not covered in the provided human-focused sources.
- Human antibodies typically use identifiers like "AT1" (angiotensin II type 1 receptor) or "IgG1," not "At1gXXXX."
Nomenclature Error:
- The term might be a typo or misreference to a gene/protein with a similar name. For example, antibodies against the AT1 receptor (e.g., in preeclampsia studies ) or Tau protein (e.g., single-domain antibodies in neurodegenerative research ) are well-documented but unrelated to "At1g50980."
Emerging or Niche Research:
- If "At1g50980" refers to a novel or understudied target, it may not yet be represented in mainstream literature. Recent advancements in recombinant antibody production or single-domain antibody engineering could theoretically apply to such targets, but no direct evidence exists in the provided sources.

Antibodies Targeting AT1 Receptors

Antibody Type	Application	Key Findings
Agonistic AT1-AA	Preeclampsia research	Induces vascular cell signaling via NF-κB/AP-1 activation, linked to tissue factor production and reactive oxygen species .
Monoclonal (6313/G2)	AT1 receptor localization studies	Recognizes extracellular domains of AT1 in mammalian tissues, validated via immunofluorescence and COS-7 transfection .
Chimeric HCAL	Antiphospholipid syndrome (APS)	Binds β2-glycoprotein I and cardiolipin, serving as a standard for IgG aCL assays .

Single-Domain Antibodies (sdAbs)

Antibody	Target	Mechanism	Outcome	Source
sdAb (T1/T2)	Pathological Tau	Unmodified sdAbs block tau toxicity; Fc-engineered subclasses enhance clearance .	Antibodies with effector function (e.g., IgG1) show superior tau clearance in vivo .
VL domains	General therapeutic	Non-aggregating VL domains exhibit high thermal stability and protease resistance .	Engineered disulfide bonds improve stability for oral therapies .

Recombinant Antibody Methods

Applications: Biochemical markers, therapeutic agents (cancer, autoimmune diseases) .
Workflow: Gene synthesis → codon optimization → expression in vectors → purification .
Challenges: Balancing yield and specificity; vector optimization critical for high-efficiency production .

Antibody Repertoire Diversification

Mechanism	Process	Impact	Source
V(D)J Recombination	Germline gene segment shuffling	Generates ~10⁵–10⁶ naive antibodies; limited by B cell numbers .
Somatic Hypermutation	Mutations in CDRs during germinal center reactions	Increases affinity (10⁶–10⁹ fold) and class switching (IgG, IgA, IgE) .

Recommendations for Further Inquiry

Verify Nomenclature: Confirm "At1g50980" refers to a correct gene/protein identifier (e.g., TAIR database for Arabidopsis).
Explore Plant-Specific Databases: Use resources like The Arabidopsis Information Resource (TAIR) or UniProt for plant antibody research.
Consult Recent Publications: Search PubMed or Google Scholar for studies post-2023, as the provided sources do not include recent updates.

Product Specs

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4

Form

Liquid

Lead Time

Made-to-order (14-16 weeks)

Synonyms

At1g50980 antibody; F8A12.20Putative FBD-associated F-box protein At1g50980 antibody

Target Names

At1g50980

Uniprot No.

Q9C6I2

Q&A

FAQs for Researchers on At1g50980 Antibody in Academic Research

The At1g50980 gene encodes a putative FBD-associated F-box protein in Nicotiana tomentosiformis, with applications in plant biology and protein interaction studies. Below are research-focused FAQs addressing experimental design, methodological challenges, and data interpretation.

Advanced Research Questions

How to resolve discrepancies in At1g50980 antibody reactivity across plant species?

Approach:
- Conduct phylogenetic alignment of At1g50980 homologs to identify conserved vs. divergent epitopes.
- Test cross-reactivity using protein extracts from related species (e.g., Nicotiana tabacum) and quantify via dose-response curves .
- If nonspecific binding occurs, refine antibody purification using antigen-affinity chromatography .

What strategies optimize At1g50980 antibody use in functional studies (e.g., protein-protein interactions)?

Recommendations:
- Combine co-immunoprecipitation (Co-IP) with mass spectrometry to identify interacting partners. Validate using in planta assays like Bimolecular Fluorescence Complementation (BiFC).
- For quantitative studies, pair antibody-based detection with stable isotope labeling (SILAC) to normalize protein abundance .

Methodological Challenges

How to address low antibody titers in polyclonal sera for At1g50980?

Solutions:
- Booster immunizations: Administer antigen at 3-week intervals and monitor serum titers via indirect ELISA .
- Use adjuvants (e.g., Freund’s complete/incomplete) to enhance immune response .
- Screen hybridoma clones for higher affinity if switching to monoclonal antibodies .

What statistical methods are appropriate for analyzing At1g50980 antibody binding kinetics?

Analysis frameworks:
- Fit nonlinear regression models (e.g., one-site binding) to Surface Plasmon Resonance (SPR) data.
- Calculate dissociation constants (K<sub>D</sub>) and compare across experimental groups using ANOVA with post-hoc Tukey tests .

Data Interpretation Tables

Table 1: Common Issues in At1g50980 Antibody Assays

Issue	Likely Cause	Mitigation Strategy
Non-specific bands in Western blot	Cross-reactivity with homologous F-box proteins	Pre-absorb antibody with heterologous plant extracts
Weak signal in immunohistochemistry	Low antigen abundance	Amplify signal using tyramide-based detection
High background in ELISA	Incomplete blocking	Use 5% BSA + 0.1% Tween-20 for blocking

Table 2: Functional Study Design for At1g50980

Objective	Technique	Key Parameters
Subcellular localization	Confocal microscopy	GFP fusion constructs, organelle markers
Protein turnover	Cycloheximide chase assay	Half-life calculation via exponential decay modeling
Knockout phenotype analysis	Phenotypic screening	Rosette size, flowering time, stress-response assays

Contradictory Data Analysis

Scenario: Conflicting results in At1g50980 protein abundance under stress conditions.
- Root cause analysis:
  - Compare antibody batches using lot-to-lot variability assays .
  - Validate via orthogonal methods (e.g., RNA-seq for transcript levels vs. antibody-based protein quantification).
  - Assess environmental variables (e.g., light exposure, nutrient availability) that may modulate protein stability .

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

At1g50980 Antibody